Arizton publishes the latest report on the cardiac biomarkers market - global outlook & forecast 2023-2028. The market is growing at a CAGR of 12.14% during 2022-2028.
To Know More, Download the Free Sample Report: https://www.arizton.com/request-sample/3980
Cardiac Biomarkers Market Report Scope
| Report Attributes | Details |
| Market Size (2028) | USD 26.43 Billion |
| Market Size (2022) | USD 13.29 Billion |
| CAGR (2022-2028) | 12.14% |
| Base Year | 2022 |
| Forecast Year | 2023-2028 |
| Market Segmentation | Biomarkers Type, Application, End-user, and Geography |
| Geographic Analysis | North America, Europe, APAC, Latin America, and Middle East & Africa |
| Market Dynamics |
|
Market Overview
The field of cardiac biomarkers has witnessed significant growth and innovation in recent decades, playing a pivotal role in the diagnosis, prognosis, and management of cardiovascular diseases (CVDs). As one of the most critical segments within the broader healthcare industry, the global cardiac biomarkers market has evolved into a competitive hub, driven by the rising prevalence of CVDs, advancements in diagnostic technologies, and the pursuit of enhanced patient outcomes.
The cardiac biomarkers market encompasses a variety of players, including pharmaceutical companies, diagnostic manufacturers, biotechnology firms, and research institutions. Leading participants in this market comprise well-established names such as Abbott, Bio-Rad Laboratories, Danaher, F. Hoffman-La Roche, PerkinElmer, and Siemens Healthineers, among others. These industry giants have traditionally held a dominant position due to their extensive resources, established distribution networks, and robust research and development capabilities. Nevertheless, smaller, innovative startups have also made their mark by introducing new biomarkers, point-of-care testing solutions, and digital health integrations.
Cardiac biomarkers play a crucial role in cardiovascular medicine, aiding in the diagnosis, risk stratification, and management of patients with various heart-related conditions. Troponins, CK-MB, BNP, NT-proBNP, myoglobin, CRP, lipid profile, and D-dimer are among the most used cardiac biomarkers, providing specific insights into cardiac health and function. Integrating these biomarkers into clinical practice allows for early detection, appropriate risk assessment, and personalized treatment plans, ultimately leading to improved patient outcomes and a better understanding of cardiovascular diseases. As research and technology advance, the repertoire of cardiac biomarkers may expand, enhancing our ability to diagnose and manage heart-related conditions with even greater precision.
Segmentation Analysis
In 2022, the global market for cardiac biomarkers can be categorized based on biomarker types, which include troponin, creatine kinase (CK-MB), myoglobin, and other biomarkers. Among these, the troponin segment held the largest market share. Troponins represent a significant advancement in the diagnosis and management of cardiovascular diseases (CVDs). These are highly specific proteins located in cardiac muscle cells and are released into the bloodstream in response to heart muscle damage. Troponin biomarkers play a pivotal role in the identification of cardiac conditions, the assessment of the severity of cardiac events, the guidance of treatment decisions, and the prediction of patient outcomes. Furthermore, the use of high-sensitivity troponin assays further enhances the ability to detect cardiac issues early, even in the absence of clinical symptoms, by identifying trace amounts of troponin in the blood.
In 2022, the global market for cardiac biomarkers can be divided by end-user into hospitals, diagnostic laboratories, and other healthcare facilities. Notably, hospitals claimed a substantial share of this end-user segment. Hospitals play a critical role as end-users of cardiac biomarkers, employing them across various facets of patient care associated with cardiovascular diseases. From the emergency department to inpatient care settings, cardiac biomarkers are of paramount importance in diagnosing acute cardiovascular events, stratifying patient risk, and informing treatment decisions. The presence and accurate interpretation of these biomarkers empower healthcare professionals to deliver timely interventions and enhance patient outcomes. By harnessing the capabilities of cardiac biomarkers, hospitals can continue to make significant advancements in enhancing the care and prognosis of patients with cardiovascular conditions.
Geographical Analysis
North America is a dominant player in the global cardiac biomarkers market. The region’s leadership is attributed to the high prevalence of CVDs, a well-established healthcare infrastructure, and robust research and development activities. The US and Canada are the primary contributors to the market’s growth in this region, focusing on introducing innovative biomarkers and diagnostic technologies. Moreover, increasing awareness about early disease detection and prevention drives the adoption of cardiac biomarkers in clinical practice.
Europe holds a significant share of the global cardiac biomarkers market due to the rising incidence of CVDs and an aging population. Germany, France, the UK, Italy, and Spain are at the forefront of technological advances and medical research in cardiovascular medicine. In addition, government initiatives to improve healthcare facilities and reduce CVD-related morbidity and mortality further boost the adoption of cardiac biomarkers in Europe.
About the Report:
The report examines the current state of the cardiac biomarkers market and its market dynamics from 2023 to 2028. It provides a comprehensive overview of various factors driving market growth, hindrances, and emerging trends. The analysis encompasses both the aspects of market demand and supply. Additionally, it offers profiles and assessments of major companies as well as several noteworthy firms in the industry.
Buy this Research Now: https://www.arizton.com/market-reports/cardiac-biomarkers-market
Post-Purchase Benefit
- 1hr of free analyst discussion
- 10% of customization
Vendors
- Abbott
- Bio-Rad Laboratories
- Danaher
- F.Hoffmann-La Roche
- PerkinElmer
- Siemens Healthineers
- Abcam
- bioMérieux
- BioSupply
- BTNX
- CardioGenics
- Creative Diagnostics
- DiaSorin
- Life Diagnostics
- LumiraDx
- Medix Biochemica
- MESO SCALE DIAGNOSTICS
- MP Biomedicals
- Quidel
- Randox Laboratories
- Response Biomedical
- Tosoh
Market Segmentation
- Biomarkers Type: Troponin, Creatine Kinase (CK-MB), Myoglobin, and Other
- Application: Acute Coronary Syndrome, Myocardial Infraction, Congestive Heart Failure, and Others
- End-user: Hospitals, Diagnostic Laboratories, and Other
- Geography: North America, Europe, APAC, Latin America, and Middle East & Africa
To Get the Benefit of Our Free Report Customization Service, Send Your Enquiry Here – https://www.arizton.com/customize-report/3980
Arizton Expertise in the Healthcare Industry
Arizton offers both syndicate and custom market intelligence & competitive intelligence solutions across MedTech, pharmaceuticals, and life sciences & biotechnology markets within the healthcare industry. Arizton’s healthcare vertical provides unbiased research and evidence-based analysis to support business decisions and comprehensive end-to-end solutions to its customers, covering all dimensions of the healthcare value chain. We track a diverse array of devices (equipment, implants, and hospital supplies) and drugs (patented, generic, & OTC) across North America, Europe, APAC, Latin America, and the Middle East & Africa regions. The healthcare reports provide historical and forecast data for 20+ key countries worldwide. We track product approvals/launches, M&A activities, and collaboration/partnership activities among pharma/biotech, medical device, and life sciences companies. Our pharmaceutical portfolio tracks 15+ therapy areas with a significant focus on immunology, oncology, rare & genetic diseases, dermatology, and metabolic diseases. Our medical devices and life sciences portfolio covers in-vitro diagnostics, healthcare IT, patient monitoring, cardiovascular devices, medical imaging, personal protective equipment, clinical laboratory services, and CMO/CDMO services.
Explore more healthcare reports: https://www.arizton.com/market-reports/category/healthcare-lifesciences
About Us:
Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.
We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.
Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.
Contact Us:
Call: +1-312-235-2040
+1 302 469 0707
Mail: enquiry@arizton.com
Contact Us: https://www.arizton.com/contact-us
Blog: https://www.arizton.com/blog
Website: https://www.arizton.com/